Jörge E. Cortes

143.3k total citations · 21 hit papers
2.3k papers, 85.0k citations indexed

About

Jörge E. Cortes is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Jörge E. Cortes has authored 2.3k papers receiving a total of 85.0k indexed citations (citations by other indexed papers that have themselves been cited), including 1.9k papers in Hematology, 1.4k papers in Genetics and 537 papers in Rheumatology. Recurrent topics in Jörge E. Cortes's work include Chronic Myeloid Leukemia Treatments (1.4k papers), Chronic Lymphocytic Leukemia Research (1.1k papers) and Acute Myeloid Leukemia Research (856 papers). Jörge E. Cortes is often cited by papers focused on Chronic Myeloid Leukemia Treatments (1.4k papers), Chronic Lymphocytic Leukemia Research (1.1k papers) and Acute Myeloid Leukemia Research (856 papers). Jörge E. Cortes collaborates with scholars based in United States, Germany and Italy. Jörge E. Cortes's co-authors include Hagop M. Kantarjian, Susan O’Brien, Francis J. Giles, Guillermo Garcia‐Manero, Farhad Ravandi, Deborah A. Thomas, Stefan Faderl, Elias Jabbour, Srđan Verstovšek and Alfonso Quintás‐Cardama and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Jörge E. Cortes

2.2k papers receiving 83.2k citations

Hit Papers

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–P... 2000 2026 2008 2017 2006 2010 2006 2009 2010 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
    2006 1.3k citations Moshe Talpaz, Neil P. Shah et al. profile →
  2. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
    2010 1.1k citations Hagop M. Kantarjian, Neil P. Shah et al. profile →
  3. Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
    2006 970 citations Hagop M. Kantarjian, Francis J. Giles et al. profile →
  4. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
    2009 890 citations Michele Baccarani, Jörge E. Cortes et al. Journal of Clinical Oncology profile →
  5. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
    2010 847 citations Srđan Verstovšek, Hagop M. Kantarjian et al. profile →
  6. Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
    2005 704 citations Michael J. Keating, Susan O’Brien et al. Journal of Clinical Oncology profile →
  7. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies
    2003 631 citations Guillermo Garcia‐Manero, Francis J. Giles et al. Blood profile →
  8. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
    2016 621 citations Jörge E. Cortes, Giuseppe Saglio et al. Journal of Clinical Oncology profile →
  9. Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
    2000 586 citations Hagop M. Kantarjian, Jörge E. Cortes et al. Journal of Clinical Oncology profile →
  10. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
    2010 586 citations Amie S. Corbin, Jörge E. Cortes et al. profile →
  11. Acute myeloid leukaemia
    2018 544 citations Jörge E. Cortes et al. profile →
  12. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
    2013 539 citations Carlos E. Bueso‐Ramos, Sherry Pierce et al. profile →
  13. Molecular biology of bcr-abl1–positive chronic myeloid leukemia
    2008 528 citations Jörge E. Cortes et al. Blood profile →
  14. Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
    2012 527 citations Jörge E. Cortes, Hagop M. Kantarjian et al. profile →
  15. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
    2006 515 citations Hagop M. Kantarjian, Guillermo Garcia‐Manero et al. Blood profile →
  16. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
    2008 508 citations Susan O’Brien, William G. Wierda et al. Blood profile →
  17. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
    2011 441 citations Hagop M. Kantarjian, Neil P. Shah et al. Blood profile →
  18. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
    2018 354 citations Jörge E. Cortes, Pau Montesinos et al. profile →
  19. Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
    2012 344 citations Jörge E. Cortes, Dong‐Wook Kim et al. Journal of Clinical Oncology profile →
  20. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
    2015 340 citations Jörge E. Cortes et al. profile →
  21. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
    2017 320 citations Jörge E. Cortes, Carlo Gambacorti‐Passerini et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jörge E. Cortes United States 139 60.4k 41.4k 23.6k 19.7k 15.4k 2.3k 85.0k
Hagop M. Kantarjian United States 171 96.4k 1.6× 64.0k 1.5× 44.3k 1.9× 25.3k 1.3× 28.5k 1.9× 3.4k 147.9k
Brian Druker United States 106 30.5k 0.5× 21.7k 0.5× 17.1k 0.7× 13.5k 0.7× 10.9k 0.7× 607 54.8k
Moshe Talpaz United States 98 29.2k 0.5× 22.8k 0.6× 11.0k 0.5× 13.1k 0.7× 8.7k 0.6× 778 44.8k
Francis J. Giles United States 105 20.4k 0.3× 15.8k 0.4× 15.0k 0.6× 6.3k 0.3× 9.3k 0.6× 786 41.9k
Guillermo Garcia‐Manero United States 106 30.6k 0.5× 14.7k 0.4× 17.8k 0.8× 4.4k 0.2× 7.5k 0.5× 1.5k 44.1k
Ayalew Tefferi United States 115 34.8k 0.6× 38.2k 0.9× 22.2k 0.9× 15.9k 0.8× 4.6k 0.3× 1.1k 54.7k
Andreas Hochhaus Germany 87 30.1k 0.5× 24.0k 0.6× 6.1k 0.3× 15.6k 0.8× 7.3k 0.5× 839 40.0k
Susan O’Brien United States 100 21.3k 0.4× 17.3k 0.4× 8.3k 0.3× 5.6k 0.3× 7.4k 0.5× 840 36.5k
Clara D. Bloomfield United States 91 28.5k 0.5× 12.1k 0.3× 17.7k 0.8× 2.1k 0.1× 6.6k 0.4× 406 42.9k
Srđan Verstovšek United States 84 18.6k 0.3× 18.7k 0.5× 12.1k 0.5× 8.5k 0.4× 4.4k 0.3× 1.1k 30.0k

Countries citing papers authored by Jörge E. Cortes

Since Specialization
Citations

This map shows the geographic impact of Jörge E. Cortes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jörge E. Cortes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jörge E. Cortes more than expected).

Fields of papers citing papers by Jörge E. Cortes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jörge E. Cortes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jörge E. Cortes. The network helps show where Jörge E. Cortes may publish in the future.

Co-authorship network of co-authors of Jörge E. Cortes

This figure shows the co-authorship network connecting the top 25 collaborators of Jörge E. Cortes. A scholar is included among the top collaborators of Jörge E. Cortes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jörge E. Cortes. Jörge E. Cortes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Diego, David Martı́n de, et al.. (2024). Designing Poisson Integrators Through Machine Learning. IFAC-PapersOnLine. 58(6). 31–35. 2 indexed citations
2.
Cortes, Jörge E.. (2020). How to manage CML patients with comorbidities. Blood. 136(22). 2507–2512. 21 indexed citations
3.
Cortes, Jörge E., Justin M. Watts, Thomas Prébet, et al.. (2018). FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study. Blood. 132(Supplement 1). 1452–1452. 14 indexed citations
4.
Savona, Michael R., Daniel A. Pollyea, Wendy Stock, et al.. (2018). Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clinical Cancer Research. 24(10). 2294–2303. 86 indexed citations
5.
Jiang, Xuejie, Po Yee Mak, Hong Mu, et al.. (2018). Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3 -Mutant Acute Myeloid Leukemia. Clinical Cancer Research. 24(10). 2417–2429. 67 indexed citations
6.
Pemmaraju, Naveen, Hagop M. Kantarjian, Joseph D. Khoury, et al.. (2017). Long-Term Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood. 130. 3855–3855. 5 indexed citations
7.
8.
Rausch, Caitlin R., Courtney D. DiNardo, Tapan M. Kadia, et al.. (2017). Results of Off-Label Venetoclax Use in Combination with Low-Intensity Chemotherapy in Patients with Relapsed and Refractory Myeloid Malignancies. Blood. 130. 1356–1356. 3 indexed citations
9.
Sasaki, Koji, Elias Jabbour, Jörge E. Cortes, et al.. (2016). Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clinical Lymphoma Myeloma & Leukemia. 16(11). 616–624. 11 indexed citations
10.
Wang, Wei, Jörge E. Cortes, Guilin Tang, et al.. (2016). Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 127(22). 2742–2750. 111 indexed citations
11.
Cortes, Jörge E., Giuseppe Saglio, Hagop M. Kantarjian, et al.. (2016). Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. Journal of Clinical Oncology. 34(20). 2333–2340. 621 indexed citations breakdown →
12.
Jaalouk, Diana E., Carlos E. Bueso‐Ramos, Laura Bover, et al.. (2015). Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens. Clinical Cancer Research. 21(13). 3041–3051. 11 indexed citations
13.
Corbin, Amie S., Thomas O’Hare, Zhimin Gu, et al.. (2013). KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors. Cancer Research. 73(18). 5775–5786. 17 indexed citations
14.
Cortes, Jörge E., Jeff H. Lipton, Delphine Réa, et al.. (2012). Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 120(13). 2573–2580. 89 indexed citations
15.
16.
Ma, Wanlong, Hagop M. Kantarjian, B. Nebiyou Bekele, et al.. (2009). Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome. Clinical Cancer Research. 15(11). 3820–3826. 40 indexed citations
17.
18.
Ravandi, Farhad, E Estey, Dan Jones, et al.. (2008). Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. Journal of Clinical Oncology. 27(4). 504–510. 270 indexed citations
19.
Cortes, Jörge E., Elias Jabbour, Hagop Kantarjian, et al.. (2007). Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 110(12). 4005–4011. 230 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hagop M. Kantarjian Breakdown of academic impact, for papers by Brian Druker Breakdown of academic impact, for papers by Moshe Talpaz Breakdown of academic impact, for papers by Francis J. Giles Breakdown of academic impact, for papers by Guillermo Garcia‐Manero Breakdown of academic impact, for papers by Ayalew Tefferi Breakdown of academic impact, for papers by Andreas Hochhaus Breakdown of academic impact, for papers by Susan O’Brien Breakdown of academic impact, for papers by Clara D. Bloomfield Breakdown of academic impact, for papers by Srđan Verstovšek
Rankless by CCL
2026